19829-32-4

Basic information

• Product Name: 1-bromo-3-propylbenzene
• Synonyms: 1-bromo-3-propylbenzene;1-BROMO-3-PROPYLBENZENE（WS201472）
• CAS NO: 19829-32-4
• Molecular Formula: C₉H₁₁Br
• Molecular Weight: 199.08764
• Mol File: 19829-32-4.mol

Chemical Properties

• Boiling Point: 96-100 °C(Press: 17 Torr)
• Appearance: /
• Density: 1.284±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-bromo-3-propylbenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-3-propylbenzene(19829-32-4)
• EPA Substance Registry System: 1-bromo-3-propylbenzene(19829-32-4)

Safety Data

• Hazardous Substances Data: 19829-32-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-bromo-3-propylbenzene is used as a building block for the synthesis of various pharmaceuticals. Its unique structure allows for the creation of a wide range of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical industry, 1-bromo-3-propylbenzene serves as a key intermediate in the production of various agrochemicals. Its versatility in organic synthesis enables the creation of compounds that can be used in pest control, crop protection, and other agricultural applications.
Used in Fine Chemicals Production:
1-bromo-3-propylbenzene is utilized as an intermediate in the production of fine chemicals. These specialty chemicals are used in various applications, including fragrances, dyes, and other high-value products.
Used as a Solvent:
Due to its properties as a liquid at room temperature, 1-bromo-3-propylbenzene can be used as a solvent in various chemical processes. Its ability to dissolve a wide range of substances makes it a valuable component in the synthesis of different compounds.
Used in Chemical Production:
1-bromo-3-propylbenzene also serves as an intermediate in the production of other chemicals. Its reactivity and functional groups make it a useful building block for creating a variety of chemical products.
Safety Precautions:

Upstream product

• 19829-31-3 1-(3-bromophenyl)-1-propanone 
• 74157-47-4 (+/-)-1-(3-bromophenyl)propanol 
• 928837-84-7 cis-3-bromo-β-methylstyrene 
• 3132-99-8 m-bromobenzoic aldehyde 
• 64-17-5 ethanol 
• 31067-20-6 β-methyl-3-bromostyrene 
• 103-65-1 phenylpropane 

Downstream Products

• 1402884-05-2 4,4,5,5-tetramethyl-2-(3-propylphenyl)-1,3,2-dioxaborolane 
• 103528-31-0 m-propylbenzaldehyde 
• 1426408-57-2 (E)-3-(3-propylphenyl)acrylonitrile 
• 1426408-58-3 (Z)-3-(3-propylphenyl)acrylonitrile 
• 1357107-88-0 2-(((3-propylphenyl)(diphenyl)methyl)sulfanyl)ethanamine 
• 1357108-49-6 diphenyl(3-propylphenyl)methanol 
• 1244763-18-5 C₁₇H₁₉N₃ 
• 125604-02-6 3-propylphenyl methanol 
• 53104-07-7 N-tert-Butyl-N-(3-propyl-phenyl)-hydroxylamine 

Relevant articles and documents

NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF

A class of compounds that bind to fatty acid binding protein (FABP4) and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4.

Ligand Dependent Switch from RXR Homo- to RXR-NURR1 Heterodimerization

Retinoid X receptors (RXRs) play key roles in many physiological processes in both the periphery and central nervous system. In addition, RXRs form heterodimers with other nuclear receptors to exert their physiological effects. The nuclear receptor relate

NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The 5 invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also 10 relates to a process for manufacturing compounds of Formula I.

Heterocyclic compound

The present invention relates to compound (I) or a salt thereof which has a ROR γ t inhibitory action. wherein each symbol is as defined in the specification.

INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES

Inhibitors of viral replication of formula (I), their process of preparation and their therapeutical uses. The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a pyrazole compound of the following general Formula [1b] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use wherein each symbol is the same as defined in the description

Triphenylbutanamines: Kinesin spindle protein inhibitors with in vivo antitumor activity

The human mitotic kinesin Eg5 represents a novel mitotic spindle target for cancer chemotherapy. We previously identified S-trityl-l-cysteine (STLC) and related analogues as selective potent inhibitors of Eg5. We herein report on the development of a series of 4,4,4-triphenylbutan-1-amine inhibitors derived from the STLC scaffold. This new generation systematically improves on potency: the most potent C-trityl analogues exhibit Kiapp ≥ 10 nM and GI50 ≈ 50 nM, comparable to results from the phase II clinical benchmark ispinesib. Crystallographic studies reveal that they adopt the same overall binding configuration as S-trityl analogues at an allosteric site formed by loop L5 of Eg5. Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition. One triphenylbutanamine analogue and ispinesib possess very good bioavailability (51% and 45%, respectively), with the former showing in vivo antitumor growth activity in nude mice xenograft studies.

SUBSTITUTED PARA-BIPHENYLOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted para-biphenyloxymethyl dihydro oxazolopyrimidinones of formula (I) as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of

2,4-Dithi(oxo)-pyrimidin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists

PCT No. PCT/SE98/01240 Sec. 371 Date Sep. 30, 1998 Sec. 102(e) Date Sep. 30, 1998 PCT Filed Jun. 25, 1998 PCT Pub. No. WO99/02501 PCT Pub. Date Jan. 21, 1999The invention relates to new pharmaceutically active compounds which are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.